EpimAb Biotherapeutics
PrivateLast Round
IPO
Dec 18, 2025
Est. Valuation
$492.3M
Total Funding Raised
$264.5M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
EpimAb Biotherapeutics is a biopharmaceutical company specializing in the research and development of innovative bispecific antibody therapeutics using its proprietary FIT-Ig technology.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
EpimAb Biotherapeutics Comparables
Compare EpimAb Biotherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Harbour BioMed | 81% | |
| Zymeworks Inc. | 78% | |
| Akeso, Inc. | 78% | |
EpimAb Biotherapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Dec 18, 2025 | ||||
| Convertible Debt | Apr 25, 2022 | ||||
| Series C | Mar 22, 2021 | ||||
| Series B Extension | Mar 11, 2020 | ||||
| Series B | Jun 5, 2019 | ||||
Series A | Apr 25, 2017 |
Key People
Founding team and executive leadership
EpimAb Biotherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| SDIC Fund Management | Series C |
| SCVC | Series B |
| Yanchuang Capital | Series C |
| Mirae Asset | Series C |
| 招银国际金融有限公司 | IPO, Series C |
| Bencao Capital | Series A |
| CITIC Securities | IPO |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 17, 2026
Presenting novel prodrug T-cell engager platform at AACR Annual Meeting.
- Feb 10, 2026
Partner Almirall filed CTA for bispecific antibody technology.
EpimAb Biotherapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about EpimAb Biotherapeutics's valuation, stock price, and market status.